Regeneron Pharmaceuticals (REGN) Downgraded by ValuEngine to Sell
ValuEngine lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.
Several other research analysts have also recently weighed in on REGN. Robert W. Baird raised shares of Regeneron Pharmaceuticals from an underperform rating to a neutral rating in a report on Friday, November 3rd. Citigroup reaffirmed a buy rating and issued a $480.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $491.00 to $479.00 and set a market perform rating on the stock in a report on Thursday, November 9th. Royal Bank of Canada reaffirmed a sector perform rating and issued a $425.00 price target (down previously from $473.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Finally, Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $490.00 to $463.00 and set an equal weight rating on the stock in a report on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals has an average rating of Hold and an average price target of $450.65.
Regeneron Pharmaceuticals (REGN) traded up $0.93 during trading on Thursday, hitting $331.40. 126,694 shares of the stock traded hands, compared to its average volume of 1,015,513. The company has a market capitalization of $35,510.00, a PE ratio of 25.15, a P/E/G ratio of 1.04 and a beta of 1.54. Regeneron Pharmaceuticals has a 52-week low of $313.53 and a 52-week high of $543.55. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Harding Loevner LP boosted its position in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after buying an additional 3,131,966 shares during the period. Renaissance Technologies LLC boosted its position in Regeneron Pharmaceuticals by 516.8% during the fourth quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock valued at $217,892,000 after buying an additional 485,600 shares during the period. Two Sigma Advisers LP purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $143,255,000. Old Mutual Global Investors UK Ltd. boosted its position in Regeneron Pharmaceuticals by 500,446.2% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after buying an additional 325,290 shares during the period. Finally, HealthCor Management L.P. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $122,187,000. Institutional investors and hedge funds own 65.62% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.